Key points
Migalastat (Galafold, approved by the FDA in August 2018 for adults) is the first oral treatment for Fabry disease. It delivers no enzyme from outside; it stabilises the patient's own — a capsule every other day instead of an infusion every two weeks.
| Where | How it helps | What human trials showed |
|---|---|---|
| Fabry disease with an amenable GLA variant | stabilises the patient's own enzyme so that it reaches the lysosome and works | FACETS, 24 months: kidney function stable — annualised change in estimated GFR −0.30 ± 0.66, measured GFR −1.51 ± 1.33 mL/min/1.73 m²; left ventricular mass index −7.7 g/m² (95% CI −15.4 to −0.01) |
| Switching from enzyme replacement infusions | a capsule every other day instead of an infusion every two weeks | ATTRACT, 57 adults, 18 months: kidney function changed comparably with infusions; left ventricular mass index −6.6 g/m² (−11.0 to −2.2), no significant change on infusions; plasma lyso-Gb3 remained low and stable |
| Gastrointestinal complaints | less diarrhoea, reflux and indigestion | improved in FACETS |
| Choosing whom to treat | a laboratory assay shows in advance whether the variant is amenable | in men the assay predicted the real-life response with sensitivity, specificity and predictive values of at least 0.875 |
How it helps
What breaks in Fabry disease
Every cell contains a lysosome, the compartment where spent material is taken apart. One of its enzymes, alpha-galactosidase A, dismantles a fat-like substance called globotriaosylceramide.
In Fabry disease the gene for that enzyme is damaged. The substance is no longer broken down and accumulates inside cells, year after year, from birth. The cells of the renal glomeruli, heart muscle, vessel walls and nerve ganglia suffer most.
Hence the recognisable sequence: in childhood, burning pain in hands and feet, heat intolerance, absent sweating and a characteristic rash; in adulthood, protein in the urine and declining kidney function, thickened heart walls, rhythm disturbances and early strokes. The gene sits on the X chromosome, so men are affected earlier and more severely — but women are not merely carriers: many develop full disease, more often with the heart predominating.
How it was treated before
Since the early 2000s there has been one answer — enzyme replacement therapy: the missing enzyme is manufactured biotechnologically and infused intravenously every two weeks. For life.
It works, but the price is high, and not only in money:
▸ an infusion of several hours every fortnight, tied to a centre or a visiting nurse;
▸ infusion reactions and antibodies against the foreign protein in some patients;
▸ the infused enzyme distributes unevenly and penetrates some tissues poorly;
▸ adolescents and young adults drop out of the schedule — and a missed dose means accumulation resumes.
The idea: repair your own enzyme rather than deliver another
The key observation is this. With many mutations the enzyme is in fact assembled — but it comes out unstable. The cell checks every new protein for correct folding; an unstable molecule fails that check and is sent for destruction before it ever reaches the lysosome. The enzyme is not so much absent as unable to reach its workplace.
Migalastat is a small molecule resembling the terminal fragment of the very substance the enzyme should break down. It sits in the active site and acts as a strut: it holds the protein in the correct shape, the protein passes quality control and reaches the lysosome — where the acidic environment and the excess of substrate displace the strut and free the enzyme to work.
The comparison that fits: enzyme replacement therapy means bringing in a new worker to replace one who dropped out. A chaperone means giving your own worker a crutch so that he can walk to the workshop. The second is cheaper and more convenient — but it requires that a worker exist at all.
Who it suits: an amenable variant
Prescription is preceded by a mandatory amenability assay. The variant is expressed in cultured cells, migalastat is added, and any increase in enzyme activity is measured. The study that validated this assay tested 600 disease-causing mutations: 268 proved amenable. In men the assay predicted the real-life response well — sensitivity, specificity and predictive values were all at least 0.875.
The assay is needed because only something that exists can be stabilised. If the mutation truncates the protein — a large deletion, a nonsense mutation, a frameshift — there is physically no enzyme, and no dose will help.
What the FACETS trial showed
Sixty-seven people with Fabry disease were enrolled: six months of double-blind comparison against placebo, then open-label treatment. Among those whose variant proved amenable, kidney function stayed stable over 24 months and left ventricular mass index fell (the numbers are in the Key points table).
Gastrointestinal complaints — diarrhoea, reflux, indigestion — improved separately. For Fabry patients this is no small matter: persistent bowel trouble often bothers them more than their kidney numbers do.
Switching from infusions: ATTRACT
The second question was practical: can someone who has received intravenous enzyme for years be moved onto capsules? ATTRACT enrolled 57 adults (56% women; 88% had multi-organ disease) and assigned them for 18 months either to migalastat or to continued infusions.
Kidney function changed comparably in both groups; left ventricular mass index fell on the capsule and did not change significantly on infusions (the numbers are in Key points). Renal, cardiac and cerebrovascular events occurred in 29% on migalastat versus 44% on infusions.
A 12-month extension produced 30-month data in 46 patients: estimated GFR remained stable in both groups, left ventricular mass fell in those switched from infusions, and 10% experienced a new clinical event. No new safety signals emerged.
How to take it
The 123 mg capsule follows a strict schedule:
▸ Strictly every other day — not daily; a missed or doubled dose breaks the schedule, which is why the manufacturer prints a calendar on the carton with punch-out circles for the off days;
▸ strictly on an empty stomach: two hours without food before and two hours after, a four-hour fasting window on each dosing day;
▸ a mandatory genetic assay before starting — and a fresh conversation if the variant turns out not to be amenable;
▸ monitoring does not stop: kidneys, heart and biomarkers are followed exactly as they were on infusions.
Who should see a doctor first
Who it is not for
▸ A non-amenable variant — the drug will not work; this is not a matter of dose or duration.
▸ Estimated GFR below 30 mL/min/1.73 m² and dialysis — migalastat is cleared by the kidneys, exposure rises substantially in severe impairment, and this group was never studied.
▸ Children and adolescents — safety and efficacy have not been established below the age of 18.
▸ Pregnancy and breastfeeding — data from three pregnancies in the trials are insufficient to judge risk.
▸ Combination with enzyme replacement therapy — the drug replaces it, it is not added to it.
Bottom line
▸ The first oral treatment for Fabry disease — a 123 mg capsule every other day instead of an intravenous infusion every fortnight.
▸ A different mechanism: not replacing the enzyme but stabilising the patient's own so that it reaches the lysosome.
▸ An assay decides who it suits: an amenable variant is required; of 600 mutations tested, 268 qualified.
▸ In amenable patients in FACETS kidney function stayed stable and cardiac mass declined.
▸ Switching from infusions is feasible: in ATTRACT renal function changed comparably and cardiac mass fell by 6.6 g/m².
Your own case — which variant you carry, what the biopsy shows and whether switching makes sense — can be reviewed at a consultation; the drug can be ordered here.
References
1. Germain DP, et al. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016;375(6):545–555. PMID 27509102
2. Hughes DA, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288–296. PMID 27834756
3. Benjamin ER, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430–438. PMID 27657681
4. Feldt-Rasmussen U, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131(1-2):219–228. PMID 33012654
5. GALAFOLD (migalastat) — US Prescribing Information, Amicus Therapeutics US, LLC.
Source: Migalastat (Galafold) in Fabry Disease: A Capsule Instead of an Infusion — But Not for Everyone — universum.earth. Dr. Pereligyn.
